Evaluation of Metformin Effects in the Chronic Phase of Spontaneous Seizures in Pilocarpine Model of Temporal Lobe Epilepsy Publisher Pubmed



Mehrabi S¹ ; Sanadgol N^{2, 3} ; Barati M⁴ ; Shahbazi A⁵ ; Vahabzadeh G^{1, 6} ; Barzroudi M⁷ ; Seifi M⁸ ; Gholipourmalekabadi M⁹ ; Golab F¹ Show Affiliations
Source: Metabolic Brain Disease Published:2018

Abstract

Temporal lobe epilepsy (TLE) is a common form of drug-resistant epilepsy that sometimes responds to dietary manipulation such as the ‘ketogenic diet’. Here we have investigated the effects of metformin in the rat pilocaroin model of TLE. Male rats were treated with intra peritoneal injection of pilocarpine hydrochloride, in dose of 360 mg/kg to induce status epilepticus (SE). At 45 day after induction of SE, metformin was injected intraperitoneally in dose of 250 mg/kg/day for 5 days. We show that metformin potently reduces the progression of seizures and blocks seizure-induced over-expression of brain-derived neurotropic factor (BDNF) and its receptor, Tropomyosin receptor kinase B (TrkB). We have shown that this reduced expression pattern is mediated by the transcriptional co-repressor CtBP (C-terminal binding protein). Moreover, metformin decreased mechanistic target of rapamycin (mTOR) activation through activation of AMP-activated protein kinase (AMPK) signaling pathway. Our findings have been shown that metformin has anticonvulsant and antiepileptic properties, and suggesting that antiglycolytic compounds such as metformin may represent a new class of drugs for treating epilepsy. © 2017, Springer Science+Business Media, LLC.